REFERENCES
1. Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: global trends, etiology and risk factors. World J Oncol 2019;10:10-27.
2. Bridgewater J, Lopes A, Wasan H, et al. Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. Ann Oncol 2016;27:134-40.
3. Huang L, Jansen L, Balavarca Y, et al. Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study. BMC Med 2018;16:125.
4. Brar G, Greten TF, Graubard BI, et al. Hepatocellular carcinoma survival by etiology: a SEER-medicare database analysis. Hepatol Commun 2020;4:1541-51.
5. Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol 2013;47 Suppl:S2-6.
6. Zhang L, Sanagapalli S, Stoita A. Challenges in diagnosis of pancreatic cancer. World J Gastroenterol 2018;24:2047-60.
7. Wang W, Wei C. Advances in the early diagnosis of hepatocellular carcinoma. Genes Dis 2020;7:308-19.
8. Kennedy T, Preczewski L, Stocker SJ, et al. Incidence of benign inflammatory disease in patients undergoing Whipple procedure for clinically suspected carcinoma: a single-institution experience. Am J Surg 2006;191:437-41.
9. Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in hepatocellular carcinoma: diagnosis, prognosis and treatment response assessment. Cells 2020;9:1370.
10. Singhi AD, Koay EJ, Chari ST, Maitra A. Early detection of pancreatic cancer: opportunities and challenges. Gastroenterology 2019;156:2024-40.
11. Buchs NC, Chilcott M, Poletti PA, Buhler LH, Morel P. Vascular invasion in pancreatic cancer: Imaging modalities, preoperative diagnosis and surgical management. World J Gastroenterol 2010;16:818-31.
12. Rehders A, Stoecklein NH, Güray A, Riediger R, Alexander A, Knoefel WT. Vascular invasion in pancreatic cancer: tumor biology or tumor topography? Surgery 2012;152:S143-51.
13. Dayimu A, Di Lisio L, Anand S, et al. Clinical and biological markers predictive of treatment response associated with metastatic pancreatic adenocarcinoma. Br J Cancer 2023;128:1672-80.
14. Sturm N, Ettrich TJ, Perkhofer L. The impact of biomarkers in pancreatic ductal adenocarcinoma on diagnosis, surveillance and therapy. Cancers 2022;14:217.
15. Zhang WH, Wang WQ, Han X, et al. Advances on diagnostic biomarkers of pancreatic ductal adenocarcinoma: a systems biology perspective. Comput Struct Biotechnol J 2020;18:3606-14.
16. Herreros-Villanueva M, Bujanda L. Non-invasive biomarkers in pancreatic cancer diagnosis: what we need versus what we have. Ann Transl Med 2016;4:134.
17. Boilève A, Hilmi M, Delaye M, Tijeras-Raballand A, Neuzillet C. Biomarkers in hepatobiliary cancers: what is useful in clinical practice? Cancers 2021;13:2708.
19. Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology 2016;278:563-77.
20. Karmazanovsky G, Gruzdev I, Tikhonova V, Kondratyev E, Revishvili A. Computed tomography-based radiomics approach in pancreatic tumors characterization. Radiol Med 2021;126:1388-95.
21. Mori M, Benedetti G, Partelli S, et al. Ct radiomic features of pancreatic neuroendocrine neoplasms (panNEN) are robust against delineation uncertainty. Phys Med 2019;57:41-6.
22. van Timmeren JE, Cester D, Tanadini-Lang S, Alkadhi H, Baessler B. Radiomics in medical imaging-“how-to” guide and critical reflection. Insights Imaging 2020;11:91.
23. Pavic M, Bogowicz M, Würms X, et al. Influence of inter-observer delineation variability on radiomics stability in different tumor sites. Acta Oncol 2018;57:1070-4.
24. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023;73:17-48.
25. Habib JR, Kinny-Köster B, van Oosten F, et al. Periadventitial dissection of the superior mesenteric artery for locally advanced pancreatic cancer: surgical planning with the “halo sign” and “string sign”. Surgery 2021;169:1026-31.
26. Kinny-Köster B, Habib JR, Wolfgang CL, He J, Javed AA. Favorable tumor biology in locally advanced pancreatic cancer-beyond CA19-9. J Gastrointest Oncol 2021;12:2484-94.
27. Chen PT, Chang D, Yen H, et al. Radiomic features at CT can distinguish pancreatic cancer from noncancerous pancreas. Radiol Imaging Cancer 2021;3:e210010.
28. Chu LC, Park S, Kawamoto S, et al. Utility of CT radiomics features in differentiation of pancreatic ductal adenocarcinoma from normal pancreatic tissue. AJR Am J Roentgenol 2019;213:349-57.
29. Qiu JJ, Yin J, Qian W, et al. A novel multiresolution-statistical texture analysis architecture: radiomics-aided diagnosis of PDAC based on plain CT images. IEEE Trans Med Imaging 2021;40:12-25.
30. Park S, Chu LC, Hruban RH, et al. Differentiating autoimmune pancreatitis from pancreatic ductal adenocarcinoma with CT radiomics features. Diagn Interv Imaging 2020;101:555-64.
31. Ren S, Zhao R, Zhang J, et al. Diagnostic accuracy of unenhanced CT texture analysis to differentiate mass-forming pancreatitis from pancreatic ductal adenocarcinoma. Abdom Radiol 2020;45:1524-33.
32. Zhang Y, Cheng C, Liu Z, et al. Radiomics analysis for the differentiation of autoimmune pancreatitis and pancreatic ductal adenocarcinoma in 18F-FDG PET/CT. Med Phys 2019;46:4520-30.
33. Ziegelmayer S, Kaissis G, Harder F, et al. Deep convolutional neural network-assisted feature extraction for diagnostic discrimination and feature visualization in pancreatic ductal adenocarcinoma (PDAC) versus autoimmune pancreatitis (AIP). J Clin Med 2020;9:4013.
34. E L, Xu Y, Wu Z, et al. Differentiation of focal-type autoimmune pancreatitis from pancreatic ductal adenocarcinoma using radiomics based on multiphasic computed tomography. J Comput Assist Tomogr 2020;44:511-8.
35. Guo C, Zhuge X, Wang Q, et al. The differentiation of pancreatic neuroendocrine carcinoma from pancreatic ductal adenocarcinoma: the values of CT imaging features and texture analysis. Cancer Imaging 2018;18:37.
36. He M, Liu Z, Lin Y, et al. Differentiation of atypical non-functional pancreatic neuroendocrine tumor and pancreatic ductal adenocarcinoma using CT based radiomics. Eur J Radiol 2019;117:102-11.
37. Li J, Lu J, Liang P, et al. Differentiation of atypical pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinomas: using whole-tumor CT texture analysis as quantitative biomarkers. Cancer Med 2018;7:4924-31.
38. Shi YJ, Zhu HT, Liu YL, et al. Radiomics analysis based on diffusion kurtosis imaging and T2 weighted imaging for differentiation of pancreatic neuroendocrine tumors from solid pseudopapillary tumors. Front Oncol 2020;10:1624.
39. Amedei A, Niccolai E, Prisco D. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy. Hum Vaccin Immunother 2014;10:3354-68.
40. Jeon SK, Lee JM, Joo I, et al. Nonhypervascular pancreatic neuroendocrine tumors: differential diagnosis from pancreatic ductal adenocarcinomas at MR imaging-retrospective cross-sectional study. Radiology 2017;284:77-87.
41. Ahmed TM, Kawamoto S, Hruban RH, Fishman EK, Soyer P, Chu LC. A primer on artificial intelligence in pancreatic imaging. Diagn Interv Imaging 2023;104:435-47.
42. Wei R, Lin K, Yan W, et al. Computer-aided diagnosis of pancreas serous cystic neoplasms: a radiomics method on preoperative MDCT images. Technol Cancer Res Treat 2019;18:1533033818824339.
43. Xie H, Ma S, Guo X, Zhang X, Wang X. Preoperative differentiation of pancreatic mucinous cystic neoplasm from macrocystic serous cystic adenoma using radiomics: preliminary findings and comparison with radiological model. Eur J Radiol 2020;122:108747.
44. Machicado JD, Koay EJ, Krishna SG. Radiomics for the diagnosis and differentiation of pancreatic cystic lesions. Diagnostics 2020;10:505.
45. Dmitriev K, Kaufman AE, Javed AA, et al. Classification of pancreatic cysts in computed tomography images using a random forest and convolutional neural network ensemble. In: Descoteaux M, Maier-hein L, Franz A, Jannin P, Collins DL, Duchesne S, editors. Medical image computing and computer assisted intervention - MICCAI 2017. Cham: Springer International Publishing; 2017. p. 150-8.
46. Tobaly D, Santinha J, Sartoris R, et al. CT-based radiomics analysis to predict malignancy in patients with intraductal papillary mucinous neoplasm (IPMN) of the pancreas. Cancers 2020;12:3089.
47. Polk SL, Choi JW, McGettigan MJ, et al. Multiphase computed tomography radiomics of pancreatic intraductal papillary mucinous neoplasms to predict malignancy. World J Gastroenterol 2020;26:3458-71.
48. Hong SB, Lee SS, Kim JH, et al. Pancreatic cancer CT: prediction of resectability according to NCCN criteria. Radiology 2018;289:710-8.
49. Zins M, Matos C, Cassinotto C. Pancreatic adenocarcinoma staging in the era of preoperative chemotherapy and radiation therapy. Radiology 2018;287:374-90.
50. Bian Y, Jiang H, Ma C, et al. Performance of CT-based radiomics in diagnosis of superior mesenteric vein resection margin in patients with pancreatic head cancer. Abdom Radiol 2020;45:759-73.
51. Chen F, Zhou Y, Qi X, et al. Radiomics-assisted presurgical prediction for surgical portal vein-superior mesenteric vein invasion in pancreatic ductal adenocarcinoma. Front Oncol 2020;10:523543.
52. Rigiroli F, Hoye J, Lerebours R, et al. CT radiomic features of superior mesenteric artery involvement in pancreatic ductal adenocarcinoma: a pilot study. Radiology 2021;301:610-22.
53. Schlanger D, Graur F, Popa C, Moiș E, Al Hajjar N. The role of artificial intelligence in pancreatic surgery: a systematic review. Updates Surg 2022;74:417-29.
54. Kambakamba P, Mannil M, Herrera PE, et al. The potential of machine learning to predict postoperative pancreatic fistula based on preoperative, non-contrast-enhanced CT: a proof-of-principle study. Surgery 2020;167:448-54.
55. Skawran SM, Kambakamba P, Baessler B, et al. Can magnetic resonance imaging radiomics of the pancreas predict postoperative pancreatic fistula? Eur J Radiol 2021;140:109733.
56. Capretti G, Bonifacio C, De Palma C, et al. A machine learning risk model based on preoperative computed tomography scan to predict postoperative outcomes after pancreatoduodenectomy. Updates Surg 2022;74:235-43.
57. Bian Y, Jiang H, Ma C, et al. CT-based radiomics score for distinguishing between grade 1 and grade 2 nonfunctioning pancreatic neuroendocrine tumors. AJR Am J Roentgenol 2020;215:852-63.
58. Bian Y, Li J, Cao K, et al. Magnetic resonance imaging radiomic analysis can preoperatively predict G1 and G2/3 grades in patients with NF-pNETs. Abdom Radiol 2021;46:667-80.
59. Bian Y, Zhao Z, Jiang H, et al. Noncontrast radiomics approach for predicting grades of nonfunctional pancreatic neuroendocrine tumors. J Magn Reson Imaging 2020;52:1124-36.
60. Choi TW, Kim JH, Yu MH, Park SJ, Han JK. Pancreatic neuroendocrine tumor: prediction of the tumor grade using CT findings and computerized texture analysis. Acta Radiol 2018;59:383-92.
61. Liang W, Yang P, Huang R, et al. A combined nomogram model to preoperatively predict histologic grade in pancreatic neuroendocrine tumors. Clin Cancer Res 2019;25:584-94.
62. Ren S, Zhao R, Cui W, et al. Computed tomography-based radiomics signature for the preoperative differentiation of pancreatic adenosquamous carcinoma from pancreatic ductal adenocarcinoma. Front Oncol 2020;10:1618.
63. Xing H, Hao Z, Zhu W, et al. Preoperative prediction of pathological grade in pancreatic ductal adenocarcinoma based on 18F-FDG PET/CT radiomics. EJNMMI Res 2021;11:19.
64. Bian Y, Guo S, Jiang H, et al. Relationship between radiomics and risk of lymph node metastasis in pancreatic ductal adenocarcinoma. Pancreas 2019;48:1195-203.
65. Gao J, Han F, Jin Y, Wang X, Zhang J. A radiomics nomogram for the preoperative prediction of lymph node metastasis in pancreatic ductal adenocarcinoma. Front Oncol 2020;10:1654.
66. Li K, Yao Q, Xiao J, et al. Contrast-enhanced CT radiomics for predicting lymph node metastasis in pancreatic ductal adenocarcinoma: a pilot study. Cancer Imaging 2020;20:12.
67. Liu P, Gu Q, Hu X, et al. Applying a radiomics-based strategy to preoperatively predict lymph node metastasis in the resectable pancreatic ductal adenocarcinoma. J Xray Sci Technol 2020;28:1113-21.
68. Lo Gullo R, Daimiel I, Morris EA, Pinker K. Combining molecular and imaging metrics in cancer: radiogenomics. Insights Imaging 2020;11:1.
69. Attiyeh MA, Chakraborty J, McIntyre CA, et al. CT radiomics associations with genotype and stromal content in pancreatic ductal adenocarcinoma. Abdom Radiol 2019;44:3148-57.
70. Iwatate Y, Hoshino I, Yokota H, et al. Radiogenomics for predicting p53 status, PD-L1 expression, and prognosis with machine learning in pancreatic cancer. Br J Cancer 2020;123:1253-61.
71. Kaissis GA, Ziegelmayer S, Lohöfer FK, et al. Image-based molecular phenotyping of pancreatic ductal adenocarcinoma. J Clin Med 2020;9:724.
72. Lim CH, Cho YS, Choi JY, et al. Imaging phenotype using 18F-fluorodeoxyglucose positron emission tomography-based radiomics and genetic alterations of pancreatic ductal adenocarcinoma. Eur J Nucl Med Mol Imaging 2020;47:2113-22.
73. Nardone V, Reginelli A, Grassi R, et al. Delta radiomics: a systematic review. Radiol Med 2021;126:1571-83.
74. Chen X, Oshima K, Schott D, et al. Assessment of treatment response during chemoradiation therapy for pancreatic cancer based on quantitative radiomic analysis of daily CTs: An exploratory study. PLoS One 2017;12:e0178961.
75. Cusumano D, Boldrini L, Yadav P, et al. Delta radiomics analysis for local control prediction in pancreatic cancer patients treated using magnetic resonance guided radiotherapy. Diagnostics 2021;11:72.
76. Nasief H, Hall W, Zheng C, et al. Improving treatment response prediction for chemoradiation therapy of pancreatic cancer using a combination of delta-radiomics and the clinical biomarker CA19-9. Front Oncol 2019;9:1464.
77. Nasief H, Zheng C, Schott D, et al. A machine learning based delta-radiomics process for early prediction of treatment response of pancreatic cancer. NPJ Precis Oncol 2019;3:25.
78. Simpson G, Spieler B, Dogan N, et al. Predictive value of 0.35 T magnetic resonance imaging radiomic features in stereotactic ablative body radiotherapy of pancreatic cancer: a pilot study. Med Phys 2020;47:3682-90.
79. Yue Y, Osipov A, Fraass B, et al. Identifying prognostic intratumor heterogeneity using pre- and post-radiotherapy 18F-FDG PET images for pancreatic cancer patients. J Gastrointest Oncol 2017;8:127-38.
80. Li X, Wan Y, Lou J, et al. Preoperative recurrence prediction in pancreatic ductal adenocarcinoma after radical resection using radiomics of diagnostic computed tomography. EClinicalMedicine 2022;43:101215.
81. Parr E, Du Q, Zhang C, et al. Radiomics-based outcome prediction for pancreatic cancer following stereotactic body radiotherapy. Cancers 2020;12:1051.
82. Tang TY, Li X, Zhang Q, et al. Development of a novel multiparametric MRI radiomic nomogram for preoperative evaluation of early recurrence in resectable pancreatic cancer. J Magn Reson Imaging 2020;52:231-45.
83. Wei M, Gu B, Song S, et al. A novel validated recurrence stratification system based on 18F-FDG PET/CT radiomics to guide surveillance after resection of pancreatic cancer. Front Oncol 2021;11:650266.
84. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases. Hepatology 2018;68:723-50.
85. Joo I, Lee JM, Yoon JH. Imaging diagnosis of intrahepatic and perihilar cholangiocarcinoma: recent advances and challenges. Radiology 2018;288:7-13.
86. Potretzke TA, Tan BR, Doyle MB, Brunt EM, Heiken JP, Fowler KJ. Imaging features of biphenotypic primary liver carcinoma (hepatocholangiocarcinoma) and the potential to mimic hepatocellular carcinoma: LI-RADS analysis of CT and MRI features in 61 cases. AJR Am J Roentgenol 2016;207:25-31.
87. Gatos I, Tsantis S, Karamesini M, et al. Focal liver lesions segmentation and classification in nonenhanced T2-weighted MRI. Med Phys 2017;44:3695-705.
88. Jansen MJA, Kuijf HJ, Veldhuis WB, Wessels FJ, Viergever MA, Pluim JPW. Automatic classification of focal liver lesions based on MRI and risk factors. PLoS One 2019;14:e0217053.
89. Li Z, Mao Y, Huang W, et al. Texture-based classification of different single liver lesion based on SPAIR T2W MRI images. BMC Med Imaging 2017;17:42.
90. Nie P, Yang G, Guo J, et al. A CT-based radiomics nomogram for differentiation of focal nodular hyperplasia from hepatocellular carcinoma in the non-cirrhotic liver. Cancer Imaging 2020;20:20.
91. Wu J, Liu A, Cui J, Chen A, Song Q, Xie L. Radiomics-based classification of hepatocellular carcinoma and hepatic haemangioma on precontrast magnetic resonance images. BMC Med Imaging 2019;19:23.
92. Liu X, Khalvati F, Namdar K, et al. Can machine learning radiomics provide pre-operative differentiation of combined hepatocellular cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma to inform optimal treatment planning? Eur Radiol 2021;31:244-55.
93. Trivizakis E, Manikis GC, Nikiforaki K, et al. Extending 2-D convolutional neural networks to 3-D for advancing deep learning cancer classification with application to MRI liver tumor differentiation. IEEE J Biomed Health Inform 2019;23:923-30.
94. Canellas R, Mehrkhani F, Patino M, Kambadakone A, Sahani D. Characterization of portal vein thrombosis (neoplastic versus bland) on CT images using software-based texture analysis and thrombus density (Hounsfield Units). AJR Am J Roentgenol 2016;207:W81-7.
95. Santambrogio R, Barabino M, D’Alessandro V, et al. Micronvasive behaviour of single small hepatocellular carcinoma: which treatment? Updates Surg 2021;73:1359-69.
96. He M, Zhang P, Ma X, He B, Fang C, Jia F. Radiomic feature-based predictive model for microvascular invasion in patients with hepatocellular carcinoma. Front Oncol 2020;10:574228.
97. Ni M, Zhou X, Lv Q, et al. Radiomics models for diagnosing microvascular invasion in hepatocellular carcinoma: which model is the best model? Cancer Imaging 2019;19:60.
98. Qu C, Wang Q, Li C, et al. A radiomics model based on Gd-EOB-DTPA-enhanced MRI for the prediction of microvascular invasion in solitary hepatocellular carcinoma ≤ 5 cm. Front Oncol 2022;12:831795.
99. Zhang W, Yang R, Liang F, et al. Prediction of microvascular invasion in hepatocellular carcinoma with a multi-disciplinary team-like radiomics fusion model on dynamic contrast-enhanced computed tomography. Front Oncol 2021;11:660629.
100. Chu H, Liu Z, Liang W, et al. Radiomics using CT images for preoperative prediction of futile resection in intrahepatic cholangiocarcinoma. Eur Radiol 2021;31:2368-76.
101. Limkin EJ, Sun R, Dercle L, et al. Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology. Ann Oncol 2017;28:1191-206.
102. Lopez A, Harada K, Mizrak Kaya D, Dong X, Song S, Ajani JA. Liquid biopsies in gastrointestinal malignancies: when is the big day? Expert Rev Anticancer Ther 2018;18:19-38.
103. Dalal V, Carmicheal J, Dhaliwal A, Jain M, Kaur S, Batra SK. Radiomics in stratification of pancreatic cystic lesions: machine learning in action. Cancer Lett 2020;469:228-37.
104. Wu M, Tan H, Gao F, et al. Predicting the grade of hepatocellular carcinoma based on non-contrast-enhanced MRI radiomics signature. Eur Radiol 2019;29:2802-11.
105. Ye Z, Jiang H, Chen J, et al. Texture analysis on gadoxetic acid enhanced-MRI for predicting Ki-67 status in hepatocellular carcinoma: a prospective study. Chin J Cancer Res 2019;31:806-17.
106. Yao S, Ye Z, Wei Y, Jiang HY, Song B. Radiomics in hepatocellular carcinoma: a state-of-the-art review. World J Gastrointest Oncol 2021;13:1599-615.
107. Miranda Magalhaes Santos JM, Clemente Oliveira B, Araujo-Filho JAB, et al. State-of-the-art in radiomics of hepatocellular carcinoma: a review of basic principles, applications, and limitations. Abdom Radiol 2020;45:342-53.
108. Castaldo A, De Lucia DR, Pontillo G, et al. State of the art in artificial intelligence and radiomics in hepatocellular carcinoma. Diagnostics 2021;11:1194.
109. Granata V, Fusco R, Belli A, et al. Conventional, functional and radiomics assessment for intrahepatic cholangiocarcinoma. Infect Agent Cancer 2022;17:13.
110. Suh SW, Lee KW, Lee JM, et al. Prediction of aggressiveness in early-stage hepatocellular carcinoma for selection of surgical resection. J Hepatol 2014;60:1219-24.
111. Kim J, Choi SJ, Lee SH, Lee HY, Park H. Predicting survival using pretreatment ct for patients with hepatocellular carcinoma treated with transarterial chemoembolization: comparison of models using radiomics. AJR Am J Roentgenol 2018;211:1026-34.
112. Reimer RP, Reimer P, Mahnken AH. Assessment of therapy response to transarterial radioembolization for liver metastases by means of post-treatment MRI-based texture analysis. Cardiovasc Intervent Radiol 2018;41:1545-56.
113. Chen S, Feng S, Wei J, et al. Pretreatment prediction of immunoscore in hepatocellular cancer: a radiomics-based clinical model based on Gd-EOB-DTPA-enhanced MRI imaging. Eur Radiol 2019;29:4177-87.
114. Sun R, Limkin EJ, Vakalopoulou M, et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol 2018;19:1180-91.
115. Zhou W, Zhang L, Wang K, et al. Malignancy characterization of hepatocellular carcinomas based on texture analysis of contrast-enhanced MR images. J Magn Reson Imaging 2017;45:1476-84.
116. Zhou Y, He L, Huang Y, et al. CT-based radiomics signature: a potential biomarker for preoperative prediction of early recurrence in hepatocellular carcinoma. Abdom Radiol 2017;42:1695-704.
117. Hu J, Wang Y, Deng L, et al. Development and validation of a nomogram for predicting the cancer-specific survival of fibrolamellar hepatocellular carcinoma patients. Updates Surg 2022;74:1589-99.
118. Liu Q, Li J, Liu F, et al. A radiomics nomogram for the prediction of overall survival in patients with hepatocellular carcinoma after hepatectomy. Cancer Imaging 2020;20:82.
119. Wang XH, Long LH, Cui Y, et al. MRI-based radiomics model for preoperative prediction of 5-year survival in patients with hepatocellular carcinoma. Br J Cancer 2020;122:978-85.
120. Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg 2015;261:947-55.
121. Ji GW, Zhu FP, Xu Q, et al. Machine-learning analysis of contrast-enhanced CT radiomics predicts recurrence of hepatocellular carcinoma after resection: a multi-institutional study. EBioMedicine 2019;50:156-65.
122. Yuan C, Wang Z, Gu D, et al. Prediction early recurrence of hepatocellular carcinoma eligible for curative ablation using a Radiomics nomogram. Cancer Imaging 2019;19:21.
123. Zhang Z, Chen J, Jiang H, et al. Gadoxetic acid-enhanced MRI radiomics signature: prediction of clinical outcome in hepatocellular carcinoma after surgical resection. Ann Transl Med 2020;8:870.
124. Ji GW, Zhang YD, Zhang H, et al. Biliary tract cancer at CT: a radiomics-based model to predict lymph node metastasis and survival outcomes. Radiology 2019;290:90-8.
125. Peng YT, Zhou CY, Lin P, et al. Preoperative ultrasound radiomics signatures for noninvasive evaluation of biological characteristics of intrahepatic cholangiocarcinoma. Acad Radiol 2020;27:785-97.
126. Xu L, Yang P, Liang W, et al. A radiomics approach based on support vector machine using MR images for preoperative lymph node status evaluation in intrahepatic cholangiocarcinoma. Theranostics 2019;9:5374-85.
127. Xiang F, Wei S, Liu X, Liang X, Yang L, Yan S. Radiomics analysis of contrast-enhanced CT for the preoperative prediction of microvascular invasion in mass-forming intrahepatic cholangiocarcinoma. Front Oncol 2021;11:774117.
128. Zhou Y, Zhou G, Zhang J, Xu C, Wang X, Xu P. Radiomics signature on dynamic contrast-enhanced MR images: a potential imaging biomarker for prediction of microvascular invasion in mass-forming intrahepatic cholangiocarcinoma. Eur Radiol 2021;31:6846-55.
129. Yang C, Huang M, Li S, et al. Radiomics model of magnetic resonance imaging for predicting pathological grading and lymph node metastases of extrahepatic cholangiocarcinoma. Cancer Lett 2020;470:1-7.
130. Liu Z, Wang S, Dong D, et al. The applications of radiomics in precision diagnosis and treatment of oncology: opportunities and challenges. Theranostics 2019;9:1303-22.
131. Zhao B. Understanding sources of variation to improve the reproducibility of radiomics. Front Oncol 2021;11:633176.
132. Fiz F, Costa G, Gennaro N, et al. Contrast administration impacts CT-based radiomics of colorectal liver metastases and non-tumoral liver parenchyma revealing the “Radiological” tumour microenvironment. Diagnostics 2021;11:1162.
133. Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol 2017;14:749-62.
134. Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013;501:346-54.
